In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy

Although checkpoint inhibitors (CPIs) have changed the paradigm of cancer therapy, low response rates and serious systemic adverse events remain challenging. In situ vaccine (ISV), intratumoral injection of immunomodulators that stimulate innate immunity at the tumor site, allows for the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Hirokazu, Takahashi, Ken, Yaku, Hiroaki, Kobiyama, Kouji, Iwaisako, Keiko, Zhao, Xiangdong, Shiokawa, Masahiro, Uza, Norimitsu, Kodama, Yuzo, Ishii, Ken J., Seno, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825851/
https://www.ncbi.nlm.nih.gov/pubmed/35136110
http://dx.doi.org/10.1038/s41598-022-05702-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825851/
https://www.ncbi.nlm.nih.gov/pubmed/35136110
http://dx.doi.org/10.1038/s41598-022-05702-0

Ejemplares similares